Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 and T‐20 Are Potently Synergistic in Blocking Virus‐Cell and Cell‐Cell Fusion

1 Apr 2001

Abstract excerpt

Human immunodeficiency virus type 1 (HIV-1) entry proceeds via a cascade of events that afford promising targets for therapy. PRO 542 neutralizes HIV-1 by blocking its attachment to CD4 cells, and T-20 blocks gp41-mediated fusion. Both drugs have shown promise in phase 1/2 clinical trials. Here, the drugs were tested individually and in combination in preclinical models of HIV-1 infection, and inhibition data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 11237840
DOI: 10.1086/319284

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 and T‐20 Are Potently Synergistic in Blocking Virus‐Cell and Cell‐Cell FusionPMID 11237840Read ↗

HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4.Semantic proximity Read ↗

Multi-targeting the entrance door to block HIV-1.Semantic proximity Read ↗

Synergistic In Vitro Antiretroviral Activity of a Humanized Monoclonal Anti-CD4 Antibody (TNX-355) and Enfuvirtide (T-20)Semantic proximity Read ↗

Molecular and biological interactions between two HIV-1 strains from a coinfected patient reveal the first evidence in favor of viral synergism.Semantic proximity Read ↗

Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey ModelsSemantic proximity Read ↗

Selection of T1249-resistant human immunodeficiency virus type 1 variants.Semantic proximity Read ↗

A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs.Semantic proximity Read ↗

Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1.Semantic proximity Read ↗

Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.Semantic proximity Read ↗

HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism.Semantic proximity Read ↗

Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV preventionSemantic proximity Read ↗

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In VitroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.